A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

NCT07255664 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer
Prostate Cancer Metastatic
Prostate Cancer Locally Advanced

Interventions

DRUG: CC-38
DRUG: Pembrolizumab
DRUG: Cyclophosphamid
DRUG: Interleukin-2
DRUG: Uromitexan

Sponsor

Curacell Holding AB

Collaborators

[object Object]
[object Object]
[object Object]